Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.19
-0.05 (-0.69%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 22.29, with a low estimate of 18 and a high estimate of 25. The average target predicts an increase of 210.01% from the current stock price of 7.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +247.71% | Mar 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +205.98% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +178.16% | Mar 13, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $17 → $18 | Buy | Maintains | $17 → $18 | +150.35% | Mar 12, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +247.71% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
86.76M
from 23.61M
Increased by 267.44%
Revenue Next Year
164.93M
from 86.76M
Increased by 90.10%
EPS This Year
0.17
from -2.28
EPS Next Year
0.63
from 0.17
Increased by 260.78%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 104.4M | 222.6M | 357.0M | ||
| Avg | 86.8M | 164.9M | 258.4M | ||
| Low | 56.6M | 116.0M | 197.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 342.0% | 156.6% | 116.5% | ||
| Avg | 267.4% | 90.1% | 56.7% | ||
| Low | 139.9% | 33.7% | 19.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.07 | 1.30 | 2.99 | ||
| Avg | 0.17 | 0.63 | 1.87 | ||
| Low | -0.97 | -0.04 | 1.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 650.9% | 378.3% | ||
| Avg | - | 260.8% | 199.7% | ||
| Low | - | - | 106.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.